DURECT (DRRX) Stock Price, News & Analysis

Company Overview

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Key Stats

• Today's Range: $0.76 to $0.81
• 50-Day Range: $0.75 to $0.97
• 52-Week Range: $0.68 to $1.88
• Volume: 61,803 shs
• Average Volume: 65,647 shs
• Market Capitalization: $23.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

DURECT Stock Analysis - MarketRank™

DURECT scored higher than 69% of companies evaluated by MarketBeat, and ranked 368th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DURECT has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

DURECT has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for DURECT are expected to decrease in the coming year, from ($0.50) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DURECT is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DURECT is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DURECT has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.14% of the float of DURECT has been sold short.

Short Interest Ratio / Days to Cover

DURECT has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in DURECT has recently increased by 1.26%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DURECT does not currently pay a dividend.

Dividend Growth

DURECT does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.19

Percentage of Shares Shorted

3.14% of the float of DURECT has been sold short.

Short Interest Ratio / Days to Cover

DURECT has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in DURECT has recently increased by 1.26%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.55

News Sentiment

DURECT has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for DURECT this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for DRRX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DURECT insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of DURECT is held by insiders.

Percentage Held by Institutions

Only 28.03% of the stock of DURECT is held by institutions.

DRRX Stock Analysis - Frequently Asked Questions

How have DRRX shares performed this year?

DURECT's stock was trading at $0.75 at the start of the year. Since then, DRRX stock has increased by 2.0% and is now trading at $0.7650.
View the best growth stocks for 2025 here.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) posted its quarterly earnings data on Tuesday, August, 13th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. The specialty pharmaceutical company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $2.49 million. DURECT had a negative net margin of 198.58% and a negative trailing twelve-month return on equity of 300.62%.

When did DURECT's stock split?

DURECT shares reverse split before market open on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are DURECT's major shareholders?

Top institutional shareholders of DURECT include Ingalls & Snyder LLC (5.13%) and Beirne Wealth Consulting Services LLC (1.05%). Insiders that own company stock include Judith J Robertson, Gail J Maderis, Gail M Farfel and Mohammad Azab.
View institutional ownership trends.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include CymaBay Therapeutics (CBAY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), General Electric (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 2/01/2025
• Next Earnings (Estimated): 3/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRRX
• CUSIP: N/A
• CIK: 1082038
• Web: www.durect.com
• Phone: (408) 777-1417
• Fax: 408-777-3577
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +553.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-27,620,000.00
• Net Margins: -198.58%
• Pretax Margin: -198.62%
• Return on Equity: -300.62%
• Return on Assets: -65.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: $8.59 million
• Price / Sales: 2.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.50 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 31,042,000
• Free Float: 30,049,000
• Market Cap: $23.75 million
• Optionable: Optionable
• Beta: 0.94